It seems more advantageous to identify therapeutic strategies aimed at upmodulating or downmodulating the NLRP3 inflammasome pathway at several levels than intervening on other physiopathological mechanisms characteristic of ischemic stroke. The gene discussed is NLRP3; the disease is ischemic stroke.